Results 11 to 20 of about 19,098 (162)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer

Cancer Science, Volume 114, Issue 11, Page 4343-4354, November 2023., 2023
Gilteritinib demonstrated significantly improved antitumor efficacy tha alectinib against ALK‐rearranged NSCLC cells. Abstract Gilteritinib is a multitarget tyrosine kinase inhibitor (TKI), approved for the treatment of FLT3‐mutant acute myeloid leukemia, with a broad range of activity against several tyrosine kinases including anaplastic lymphoma ...
Chihiro Ando, Eiki Ichihara, Tatsuya Nishi, Ayako Morita, Naofumi Hara, Kenji Takada, Takamasa Nakasuka, Hiromi Watanabe, Hirohisa Kano, Kazuya Nishii, Go Makimoto, Takumi Kondo, Kiichiro Ninomiya, Masanori Fujii, Toshio Kubo, Kadoaki Ohashi, Ken‐ichi Matsuoka, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura   +20 more
wiley   +1 more source

Development of mobile health–based self‐management support for patients with lung cancer: A stepwise approach

Nursing Open, Volume 9, Issue 3, Page 1612-1624, May 2022., 2022
Abstract Aim To develop self‐management support platform on mobile for Chinese patients with lung cancer. Design A stepwise approach with combination of methods. Methods Literature review was carried out to construct preliminary framework and develop detailed content for self‐management modules.
Xiaosha Ni, Yan Lou, Wenyi Hu, Hemei Wang, Hong Xu, Shuaini Li, Yunxian Zhou, Yisha Ni   +7 more
wiley   +1 more source

Clinical features and outcomes of patients with stage I multiple primary lung cancers

Cancer Science, Volume 112, Issue 5, Page 1924-1935, May 2021., 2021
This study determined the clinical features and outcomes of synchronous and metachronous multiple primary lung cancer. This information could have major implications regarding diagnosis and identification of independent prognostic factors, and provide valuable information for postoperative management of patients with multiple primary lung cancer ...
Yasushi Shintani, Jiro Okami, Hiroyuki Ito, Takashi Ohtsuka, Shinichi Toyooka, Takeshi Mori, Shun‐ichi Watanabe, Hisao Asamura, Masayuki Chida, Hiroshi Date, Shunsuke Endo, Takeshi Nagayasu, Ryoichi Nakanishi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino, on behalf of The Japanese Joint Committee of Lung Cancer Registry   +16 more
wiley   +1 more source

The effect of anticancer treatment on cancer patients with COVID‐19: A systematic review and meta‐analysis

Cancer Medicine, Volume 10, Issue 3, Page 1043-1056, February 2021., 2021
No significant difference was seen in any anticancer treatments in solid tumor subgroup. Chemotherapy, however, will lead to a higher mortality in patients with hematological malignancies. Abstract Background The relationship between cancer and COVID‐19 has been revealed during the pandemic.
Hanqing Liu, Dan Yang, Xinyue Chen, Zhihong Sun, Yutong Zou, Chuang Chen, Shengrong Sun   +6 more
wiley   +1 more source

Chinese Medical Entity Recognition Model Based on Character and Word Vector Fusion

Scientific Programming, Volume 2021, Issue 1, 2021., 2021
The medical information carried in electronic medical records has high clinical research value, and medical named entity recognition is the key to extracting valuable information from large‐scale medical texts. At present, most of the studies on Chinese medical named entity recognition are based on character vector model or word vector model.
Qinghui Zhang, Lei Hou, Pengtao Lv, Mengya Zhang, Hongwei Yang, Jianping Gou   +5 more
wiley   +1 more source

A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients

Cancer Science, Volume 111, Issue 5, Page 1685-1691, May 2020., 2020
This study provides the benchmark statistics on medically treated patients with lung cancer in Japan. Here, 3‐year survival rates of patients treated with concurrent chemoradiotherapy (n = 1689), sequential chemoradiotherapy (n = 221), thoracic radiotherapy alone (n = 662), chemotherapy alone (n = 7790) and palliative care alone (n = 1952) were 43.6 ...
Ikuo Sekine, Yasushi Shintani, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Hirotoshi Dosaka‐Akita, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura, Ichiro Yoshino   +12 more
wiley   +1 more source

Abstracts

, 2022
Cancer Science, Volume 113, Issue S1, Page 1-1874, February 2022.
wiley   +1 more source

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

Cancer Medicine, Volume 8, Issue 4, Page 1521-1529, April 2019., 2019
It remains unclear EGFR‐mutated patients who have clinical outcomes of Immune checkpoint inhibitors (ICIs). In this study, we revealed the clinical factor of ICI responders among EGFR‐mutated NSCLC. Uncommon mutation and without T790M mutation are associated to ICI efficacy.
Tadaaki Yamada, Soichi Hirai, Yuki Katayama, Akihiro Yoshimura, Shinsuke Shiotsu, Satoshi Watanabe, Toshiaki Kikuchi, Kazuki Hirose, Yutaka Kubota, Yusuke Chihara, Taishi Harada, Keiko Tanimura, Takayuki Takeda, Nobuyo Tamiya, Yoshiko Kaneko, Junji Uchino, Koichi Takayama   +16 more
wiley   +1 more source

Abstracts of the 79th Annual Meeting of the Japanese Cancer Association; 2020 Oct 1‐3; Hiroshima, Japan as Cancer Science, Supplement 1, Vol 112 (2021)

, 2021
Cancer Science, Volume 112, Issue S1, Page 1-1072, February 2021.
wiley   +1 more source

Implications of Tobacco Use on Pathogen‐Driven Diseases: A Public Health and Policy Perspective

World Medical &Health Policy, Volume 17, Issue 3, Page 468-474, September 2025.
ABSTRACT The tobacco epidemic remains one of the most significant global public health challenges, responsible for over 8 million deaths annually, with a substantial portion occurring among non‐smokers exposed to second‐hand smoke. While cigarette smoking remains the most prevalent form of tobacco use worldwide, the rise of electronic nicotine delivery
Nadine Kabbani, James L. Olds
wiley   +1 more source